

Phuong L Mai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5977948/publications.pdf>

Version: 2024-02-01

53
papers

3,590
citations

185998

28
h-index

161609

54
g-index

56
all docs

56
docs citations

56
times ranked

6696
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
2	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
3	Risks of first and subsequent cancers among <i>TP53</i> mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. <i>Cancer</i> , 2016, 122, 3673-3681.	2.0	346
4	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
5	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. <i>JAMA Oncology</i> , 2017, 3, 1634.	3.4	148
6	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 652-657.	3.2	138
7	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
8	Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199. <i>Journal of Clinical Oncology</i> , 2014, 32, 3275-3283.	0.8	115
9	Germline <i>TP53</i> Variants and Susceptibility to Osteosarcoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	109
10	Awareness of Cancer Susceptibility Genetic Testing. <i>American Journal of Preventive Medicine</i> , 2014, 46, 440-448.	1.6	107
11	Combined genetic and splicing analysis of <i>BRCA1</i> c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. <i>Human Molecular Genetics</i> , 2016, 25, 2256-2268.	1.4	106
12	A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 594-604.	1.1	99
13	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3628-3637.	3.2	99
14	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
15	Confirmation of Family Cancer History Reported in a Population-Based Survey. <i>Journal of the National Cancer Institute</i> , 2011, 103, 788-797.	3.0	91
16	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88
17	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
18	Specifications of the ACMG/AMP variant interpretation guidelines for germline <i>TP53</i> variants. <i>Human Mutation</i> , 2021, 42, 223-236.	1.1	81

#	ARTICLE	IF	CITATIONS
19	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
20	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
21	Challenges Related to Developing Serum-Based Biomarkers for Early Ovarian Cancer Detection. <i>Cancer Prevention Research</i> , 2011, 4, 303-306.	0.7	46
22	Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort. <i>JAMA Oncology</i> , 2017, 3, 1640.	3.4	43
23	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 492-499.	0.8	42
24	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
25	Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. <i>Journal of Clinical Investigation</i> , 2016, 127, 132-136.	3.9	39
26	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34
27	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
28	Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1787-1798.	5.1	29
29	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
30	Research participant interest in primary, secondary, and incidental genomic findings. <i>Genetics in Medicine</i> , 2016, 18, 1218-1225.	1.1	24
31	Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome. <i>Journal of Genetic Counseling</i> , 2016, 25, 529-542.	0.9	24
32	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
33	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
34	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. <i>Familial Cancer</i> , 2009, 8, 451-456.	0.9	21
35	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 122-129.	0.6	21
36	Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among <i>BRCA1/2</i> carriers. <i>Health Psychology</i> , 2015, 34, 709-717.	1.3	19

#	ARTICLE	IF	CITATIONS
37	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19
38	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
39	Knowledge and opinions regarding <i>BRCA1</i> and <i>BRCA2</i> genetic testing among primary care physicians. <i>Journal of Genetic Counseling</i> , 2020, 29, 122-130.	0.9	16
40	Estimating <i>TP53</i> Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 837-844.	1.1	14
41	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <i>JNCI Cancer Spectrum</i> , 2020, 4, p4z075.	1.4	11
42	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	1.1	10
43	A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentiginos and renal carcinoma in association with familial testicular germ cell malignancy: A case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 9.	0.4	9
44	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2020, 156, 131-139.	0.6	8
45	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 927-935.	1.1	7
46	Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa063.	1.4	6
47	The Fallopian Tube: From Back Stage to Center Stage. <i>Cancer Prevention Research</i> , 2015, 8, 339-341.	0.7	5
48	Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A Survey of Current Practice. <i>JCO Precision Oncology</i> , 2022, 6, e2100409.	1.5	5
49	A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome. <i>Genome Research</i> , 2020, 30, 1170-1180.	2.4	4
50	Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 393-401.	1.1	4
51	Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome. <i>Familial Cancer</i> , 2022, 21, 333-336.	0.9	1
52	Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study. <i>American Journal of Obstetrics and Gynecology</i> , 2022, , .	0.7	1
53	Urgent cancer genetic counseling and testing for young, premenopausal women with breast cancer (BC): Impact on surgical decision-making for contralateral risk-reducing mastectomy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1533-1533.	0.8	0